Weekly paclitaxel in women age 65 and above with metastatic breast cancer

Edith A. Perez, Charles Vogel, David H. Irwin, Jeffrey J. Kirshner, Ravi Patel

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age ≥65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and ≥65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.

Original languageEnglish
Pages (from-to)85-88
Number of pages4
JournalBreast Cancer Research and Treatment
Volume73
Issue number1
DOIs
StatePublished - Jun 3 2002
Externally publishedYes

Fingerprint

Paclitaxel
Breast Neoplasms
Survival Rate
Age Groups
Incidence
Therapeutics

Keywords

  • Breast cancer
  • Elderly
  • Metastatic
  • Paclitaxel
  • Weekly

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Weekly paclitaxel in women age 65 and above with metastatic breast cancer. / Perez, Edith A.; Vogel, Charles; Irwin, David H.; Kirshner, Jeffrey J.; Patel, Ravi.

In: Breast Cancer Research and Treatment, Vol. 73, No. 1, 03.06.2002, p. 85-88.

Research output: Contribution to journalArticle

Perez, Edith A. ; Vogel, Charles ; Irwin, David H. ; Kirshner, Jeffrey J. ; Patel, Ravi. / Weekly paclitaxel in women age 65 and above with metastatic breast cancer. In: Breast Cancer Research and Treatment. 2002 ; Vol. 73, No. 1. pp. 85-88.
@article{d5773ccc0ca146e091f23a53bff72b1b,
title = "Weekly paclitaxel in women age 65 and above with metastatic breast cancer",
abstract = "We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age ≥65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and ≥65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.",
keywords = "Breast cancer, Elderly, Metastatic, Paclitaxel, Weekly",
author = "Perez, {Edith A.} and Charles Vogel and Irwin, {David H.} and Kirshner, {Jeffrey J.} and Ravi Patel",
year = "2002",
month = "6",
day = "3",
doi = "10.1023/A:1015230212550",
language = "English",
volume = "73",
pages = "85--88",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Weekly paclitaxel in women age 65 and above with metastatic breast cancer

AU - Perez, Edith A.

AU - Vogel, Charles

AU - Irwin, David H.

AU - Kirshner, Jeffrey J.

AU - Patel, Ravi

PY - 2002/6/3

Y1 - 2002/6/3

N2 - We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age ≥65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and ≥65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.

AB - We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age ≥65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and ≥65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.

KW - Breast cancer

KW - Elderly

KW - Metastatic

KW - Paclitaxel

KW - Weekly

UR - http://www.scopus.com/inward/record.url?scp=0035985491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035985491&partnerID=8YFLogxK

U2 - 10.1023/A:1015230212550

DO - 10.1023/A:1015230212550

M3 - Article

VL - 73

SP - 85

EP - 88

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -